You are here
bioMérieux – Second-Quarter 2018 Business Review18 July, 2018
- Strong sales dynamic confirmed in second quarter, leading to sales up 10.4% over the first half at constant exchange rates and scope of consolidation:
- €1,169 million in sales
- Up 3.1% as reported
- Growth driven by robust molecular biology and microbiology lines and by industrial applications.
Alexandre Mérieux, Chairman and Chief Executive Officer, said: “After a first quarter in which sales were particularly high due to the flu season, the second quarter of 2018 was another period of strong sales performance for bioMérieux with organic growth of 8.4%. The Group’s balanced and diversified geographic footprint and its comprehensive offering based on three key technologies of in vitro diagnostics were major factors in its success in the second quarter.”
Marcy l'Etoile (France), July 18, 2018 – bioMérieux, a world leader in the field of in vitro diagnostics, today released its quarterly business review as at June 30, 2018.
bioMérieux’s consolidated sales amounted to €1,169 million for the first six months of 2018, versus €1,134 million for the same period one year earlier. Sales grew by 10.4% year-on-year at constant exchange rates and scope of consolidation. As expected, reported growth was once again impacted by a negative currency effect of around €83 million to stand at 3.1%.
bioMérieux Sweden AB - Hantverksvägen 15 - SE-436 33 Askim, SWEDEN